Abstract
Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Current Cancer Therapy Reviews
Title: NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Volume: 4 Issue: 2
Author(s): Renu Datta, Catherine L. Riley, Italo A. Dodi and Robert C. Rees
Affiliation:
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Abstract: Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Export Options
About this article
Cite this article as:
Datta Renu, Riley L. Catherine, Dodi A. Italo and Rees C. Robert, NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310133
DOI https://dx.doi.org/10.2174/157339408784310133 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?
Current Pharmaceutical Biotechnology DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives
Current Molecular Pharmacology The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Current Signal Transduction Therapy Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles
Current Drug Delivery Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Experimental Benefits of Sex Hormones on Vascular Function and the Outcome of Hormone Therapy in Cardiovascular Disease
Current Cardiology Reviews Albumin-Based Nanodevices as Drug Carriers
Current Pharmaceutical Design Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Laparoscopic Approach for Surgical Staging in Early Endometrial Cancer
Current Women`s Health Reviews Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Construction and Comprehensive Analysis of a Special Competitive Endogenous RNAs Network to Reveal Potential Prognostic Biomarkers for Endometrial Carcinoma
Current Bioinformatics Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?
Current Pharmaceutical Design Synthesis and Biological Evaluation of the Salicylamide and Salicylic Acid Derivatives as Anti-Estrogen Agents
Medicinal Chemistry Factors Regulating Human Extravillous Trophoblast Invasion: Chemokine-peptidase and CD9-integrin Systems
Current Pharmaceutical Biotechnology Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters